151 related articles for article (PubMed ID: 21299739)
21. Clinical efficacy, safety and pharmacokinetic properties of the plasma-derived factor IX concentrate Haemonine in previously treated patients with severe haemophilia B.
Serban M; Skotnicki AB; Colovic M; Jinca C; Klukowska A; Laguna P; Wolf DM
Haemophilia; 2012 Mar; 18(2):175-81. PubMed ID: 21812863
[TBL] [Abstract][Full Text] [Related]
22. [Successful management of neurosurgical procedures with continuous infusion of recombinant factor IX in a child with hemophilia B].
Yamamoto M; Nakadate H; Iguchi U; Masuda H; Sakai H; Ishiguro A
Rinsho Ketsueki; 2013 Mar; 54(3):300-4. PubMed ID: 23676647
[TBL] [Abstract][Full Text] [Related]
23. In vivo recovery of factor VIII and factor IX: intra- and interindividual variance in a clinical setting.
Björkman S; Folkesson A; Berntorp E
Haemophilia; 2007 Jan; 13(1):2-8. PubMed ID: 17212717
[TBL] [Abstract][Full Text] [Related]
24. Population pharmacokinetics of plasma-derived factor IX in adult patients with haemophilia B: implications for dosing in prophylaxis.
Björkman S; Ahlén V
Eur J Clin Pharmacol; 2012 Jun; 68(6):969-77. PubMed ID: 22281721
[TBL] [Abstract][Full Text] [Related]
25. Replacement therapy with recombinant factor IX. A multicentre evaluation of current dosing practices in Italy.
Rocca A; Pizzinelli S; Oliovecchio E; Santagostino E; Rocino A; Iorio A;
Blood Transfus; 2011 Jan; 9(1):60-9. PubMed ID: 21084016
[TBL] [Abstract][Full Text] [Related]
26. Preclinical studies of recombinant factor IX.
Schaub R; Garzone P; Bouchard P; Rup B; Keith J; Brinkhous K; Larsen G
Semin Hematol; 1998 Apr; 35(2 Suppl 2):28-32. PubMed ID: 9565164
[TBL] [Abstract][Full Text] [Related]
27. Pharmacokinetic properties of IB1001, an investigational recombinant factor IX, in patients with haemophilia B: repeat pharmacokinetic evaluation and sialylation analysis.
Martinowitz U; Shapiro A; Quon DV; Escobar M; Kempton C; Collins PW; Chowdary P; Makris M; Mannucci PM; Morfini M; Valentino LA; Gomperts E; Lee M
Haemophilia; 2012 Nov; 18(6):881-7. PubMed ID: 22764744
[TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetics of recombinant factor IX after intravenous and subcutaneous administration in dogs and cynomolgus monkeys.
McCarthy K; Stewart P; Sigman J; Read M; Keith JC; Brinkhous KM; Nichols TC; Schaub RG
Thromb Haemost; 2002 May; 87(5):824-30. PubMed ID: 12038784
[TBL] [Abstract][Full Text] [Related]
29. PROLONG-9FP clinical development program--phase I results of recombinant fusion protein linking coagulation factor IX with recombinant albumin (rIX-FP).
Santagostino E
Thromb Res; 2013 Mar; 131 Suppl 2():S7-10. PubMed ID: 23537724
[TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetics, thrombogenicity and safety of a double viral inactivated factor IX concentrate compared with a prothrombin complex concentrate.
Ruiz-Sáez A; Hong A; Arguello A; Echenagucia M; Boadas A; Fabbrizzi F; Minichilli F; Bosch NB
Haemophilia; 2005 Nov; 11(6):583-8. PubMed ID: 16236107
[TBL] [Abstract][Full Text] [Related]
31. Pharmacokinetics, efficacy and safety of BAX326, a novel recombinant factor IX: a prospective, controlled, multicentre phase I/III study in previously treated patients with severe (FIX level <1%) or moderately severe (FIX level ≤2%) haemophilia B.
Windyga J; Lissitchkov T; Stasyshyn O; Mamonov V; Rusen L; Lamas JL; Oh MS; Chapman M; Fritsch S; Pavlova BG; Wong WY; Abbuehl BE
Haemophilia; 2014 Jan; 20(1):15-24. PubMed ID: 23834666
[TBL] [Abstract][Full Text] [Related]
32. Pharmacokinetic study of a high-purity factor IX concentrate (Factor IX Grifols) with a 6-month follow up in previously treated patients with severe haemophilia B.
Aznar JA; Cabrera N; Matysiak M; Zawilska K; Gercheva L; Antonov A; Montañés M; Páez AM; Lissitchkov T
Haemophilia; 2009 Nov; 15(6):1243-8. PubMed ID: 19659601
[TBL] [Abstract][Full Text] [Related]
33. Differential investigations from plasma-derived and recombinant Factor IX revealed major differences in post-translational modifications of activation peptides.
Chevreux G; Faid V; Andre MH; Tellier Z; Bihoreau N
Vox Sang; 2013 Feb; 104(2):171-4. PubMed ID: 22958127
[TBL] [Abstract][Full Text] [Related]
34. Progress in the treatment of bleeding disorders.
Bergman GE
Thromb Res; 2011 Jan; 127 Suppl 1():S3-5. PubMed ID: 21035836
[TBL] [Abstract][Full Text] [Related]
35. Phase I/II, open-label, multicenter, safety, efficacy and PK study of a recombinant coagulation factor IX albumin fusion protein (rIX-FP) in subjects with hemophilia B.
Martinowitz U; Lubetsky A
Thromb Res; 2013 Mar; 131 Suppl 2():S11-4. PubMed ID: 23537721
[TBL] [Abstract][Full Text] [Related]
36. Genetic fusion to albumin improves the pharmacokinetic properties of factor IX.
Metzner HJ; Weimer T; Kronthaler U; Lang W; Schulte S
Thromb Haemost; 2009 Oct; 102(4):634-44. PubMed ID: 19806248
[TBL] [Abstract][Full Text] [Related]
37. Prophylaxis in factor IX deficiency product and patient variation.
Kisker CT; Eisberg A; Schwartz B;
Haemophilia; 2003 May; 9(3):279-84. PubMed ID: 12694518
[TBL] [Abstract][Full Text] [Related]
38. The role of Rixubis™ in the treatment of hemophilia B.
Valentino LA
Immunotherapy; 2014; 6(4):381-94. PubMed ID: 24815779
[TBL] [Abstract][Full Text] [Related]
39. The safety and efficacy of recombinant human blood coagulation factor IX in previously untreated patients with severe or moderately severe hemophilia B.
Shapiro AD; Di Paola J; Cohen A; Pasi KJ; Heisel MA; Blanchette VS; Abshire TC; Hoots WK; Lusher JM; Negrier C; Rothschild C; Roth DA
Blood; 2005 Jan; 105(2):518-25. PubMed ID: 15383463
[TBL] [Abstract][Full Text] [Related]
40. The manufacturing process for recombinant factor IX.
Harrison S; Adamson S; Bonam D; Brodeur S; Charlebois T; Clancy B; Costigan R; Drapeau D; Hamilton M; Hanley K; Kelley B; Knight A; Leonard M; McCarthy M; Oakes P; Sterl K; Switzer M; Walsh R; Foster W
Semin Hematol; 1998 Apr; 35(2 Suppl 2):4-10. PubMed ID: 9565160
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
